Abbott (NYSE: ABT) earned FDA approval for its new dual-energy catheter, TactiFlex Duo sensor-enabled ablation catheter. TactiFlex Duo joins Johnson & Johnson MedTech’s ThermoCool SmartTouch SF and Medtronic’s Affera Sphere-9 catheter in the U.S. dual-energy ablation catheter market. Medtronic won its Sphere-9 approval in 2024, and J&J earned FDA approval for its system in July […]
Abbott
Abbott’s next-generation Amulet LAA occlusion device earns CE Mark
Abbott’s (NYSE: ABT) Amulet 360 left atrial appendage (LAA) occlusion device received CE mark, the company announced today. The next-generation minimally invasive device is designed to reduce the risk of stroke in patients with non-valvular atrial fibrillation (AFib) by helping seal the LAA of the patient’s heart. Amulet 360 features a redesigned dual-seal technology that […]
MiniMed Flex now integrated with Abbot’s Instinct sensor
MiniMed (Nasdaq: MMED) announced that the MiniMed Flex system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott. The MiniMed Flex system is MiniMed’s smallest and only app-controlled insulin pump. According to the company, Instinct is the world’s smallest sensor and offers up to 15 days of wear. Powered by SmartGuard technology, MiniMed Flex automatically adjusts insulin delivery, and the Meal Detection technology can […]
Abbott opposes consolidation of spinal cord stimulation lawsuits
Abbott (NYSE: ABT) has filed a motion opposing the creation of a multidistrict litigation that would consolidate 23 personal injury lawsuits involving the manufacturer’s spinal cord stimulation devices into a single case before the Central District of California. Abbott is one of many device manufacturers facing mounting litigation related to SCS devices. Lawsuits against Boston […]
Abbott, Google to deliver glucose insights through artificial intelligence
Abbott (NYSE: ABT) is turning to Google’s artificial intelligence expertise to leverage more glucose insights for users of the Abbott Park, Illinois–based life science giant’s Lingo biowearable. Under a multiyear agreement announced today, ongoing glucose insights from Abbott’s Lingo biowearable will combine with Google Health’s technology to provide a more comprehensive view of people’s health. […]
Diabetes Technology Innovations Special Report — 2026
Last year, MassDevice and Drug Delivery Business News rolled out the first edition of their Diabetes Technology Innovations Special Report. Now, we have the second edition available for free download, providing an in-depth overview of where the diabetes industry currently stands after another year of innovation and growth. The diabetes tech industry delivers some of the most advanced combinations of […]
Abbott initiates real-world study of TriClip in leaky heart valves
Abbott (NYSE:ABT) today announced that it initiated the TREAT TR study, a post-market study evaluating its TriClip TEER system. The TriClip transcatheter edge-to-edge repair (TEER) system offers an option for those who aren’t good candidates for surgery and continue to have symptoms or persistent tricuspid regurgitation (TR) despite treatment with medical therapy. Delivered through a […]
Abbott to launch Libre Duo dual sensor internationally in the fall, expects future reimbursement catalysts
Abbott (NYSE:ABT) plans to launch its Libre Duo dual glucose-ketone sensor internationally in the fall, company leadership said today. CEO and Chair Robert B. Ford said on the company’s second-quarter earnings call that Abbott expects the launch in a few months, following CE mark approval for the multi-analyte sensor in May. Branded as Libre Duo […]
Abbott raises 2026 EPS guidance on Q2 beats, several product launches planned
Abb0tt (NYSE:ABT) today posted second-quarter financial results that topped Wall Street forecasts, leading to an increase in its earnings guidance. The company now expects adjusted EPS to range between $5.45 and $5.60 for the full year. It projects sales growth between 6.5% and 7.5%. While sales guidance remains the same as previously touted, the company […]
Abbott gets FDA nod for longer length Esprit BTK drug-eluting scaffold
Abbott (NYSE:ABT) announced today that the FDA approved the longer length (76 mm) Esprit BTK drug-eluting scaffold system. The longer Esprit BTK system received approval for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD). CLTI can cause extreme pain, open wounds that don’t heal and, in some cases, […]
AtaCor treats first patient in EV-ICD lead study in partnership with Abbott
AtaCor Medical announced today that it enrolled the first patient in its ALARION-EV extravascular implantable cardioverter-defibrillator (EV-ICD) trial. ALARION-EV evaluates a next-generation parasternal EV-ICD system. It features AtaCor’s Atala lead in combination with an EV-ICD pulse generator developed by Abbott. The study evaluates the system in patients indicated for a standard ICD but do not […]
